REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) Immunization Studies With Attenuated Strains of Bacillus anthracis (Running title: B. anthracis immunization studies)		5. TYPE OF REPORT & PERIOD COVERED
		6. PERFORMING ORG. REPORT NUMBER
7. AUTHOR(s) B.E. Ivins, J. W. Ezzell, Jr., J. Jemski, K. W. Hedlund, J. D. Ristroph, and S. H. Leppla		8. CONTRACT OR GRANT NUMBER(s)
PERFORMING ORGANIZATION NAME AND ADDRESS United States Army Medical Research Institute Of Infectious Diseases Fort Detrick, Frederick, MD 21701-5Q12		10. PROGRAM ELEMENT.PROJECT, TASK AREA & WORK UNIT NUMBERS MIDA P623763.807AA
11. CONTROLLING OFFICE NAME AND ADDRESS Research and Development Command		12. REPORT DATE 29 OCT 85
		13. NUMBER OF PAGES 22
14. MONITORING AGENCY NAME & ADDRESS(if different from Controlling Office)		15. SECURITY CLASS. (of this report) UNCLASSIFIED
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE N/A

16. DISTRIBUTION STATEMENT (of this Report)

Approved for public release; distribution unlimited

DTIC
ELECTE
DEC 0 4 1985
E

17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)

19. KEY WORDS (Continue on reverse side if necessary and identify by block number)

Bacillus anthracis, plasmid, toxin, protective antigen, capsule, vaccine, Pasteur

20. ABSTRACT (Continue on reverse side if necessary and identify by block number)
Live, attenuated strains of Bacillus anthracis lacking either the capsule plasmid pX02, the toxin plasmid pX01, or both plasmids, were tested for their efficacy as vaccines against intravenous anthrax toxin challenge in Fischer 344 rats and against aerosol or intramuscular, virulent anthrax spore challenge in Hartley guinea pigs. Only those animals immunized with toxigenic, non-encapsulated (pX01+, pX02-) strains survived toxin or spore challenge and demonstrated post-immunization antibody titers to the three components of anthrax (protective antigen, lethal factor, and edema factor). Immunization with two

DD FORM 1473 EDITION OF 1 NOV 65 IS OBSOLETE

85 12 2 010

20.
non-toxigenic, encapsulated (pX01-, pX02+), Pasteur vaccine strains neither
provided protection nor elicited titers to any of the toxin components.
Therefore to successfully immunize against anthrax toxin or spore challenge,
attenuated, live strains of B. anthracis must produce toxin components
specified by the pX01 plasmid.

DISPOSITION FORM

For use of this form, see AR 340-15; the proponent agency is TAGO.

REFERENCE OR OFFICE SYMBOL	SUBJECT
SGRD-UIB	Submission of Manuscript for Clearance

THRU Chief, Bact Div Deputy for Rsch	FROM Dr. B. E. Ivins Bacteriology Div	DATE 25 Oct 85	CMT 1 11s/7341

To Cdr, USAMRIID

1. Reference USAMRIID Memorandum No. 360-1, the abstract entitled, "Immunization Studies with Attenuated Strains of Bacillus anthracis," by B. E. Ivins, J. W. Ezzell, Jr., J. Jemski, K. W. Hedlund, J. D. Ristroph, and S. H. Leppla is submitted for clearance.

2. This abstract has been reviewed by the Editor, Dr. Susan L. Welkos, Dr. Gregory B. Knudson, and Mr. Stephen F. Little.

3. Following clearance, subject manuscript will be submitted to Infection and Immunity for publication.

1 Encl
Manuscript

Bruce E. Ivins, Ph.D.
Bacteriology Division
USAMRIID

SGRD-UIZ-D

THRU C, Bacti Div	FROM Cdr, USAMRIID	DATE 29 Oct 85	CMT 2 pkb/2285

TO   Bruce E. Ivins, Ph.D.

This manuscript has been cleared for publication and/or presentation. Follow the procedure outlined in USAMRIID Memo 360-1, dtd 1 August 1984.

Encl

DAVID L. HUXSOLL
Colonel, VC
Commanding

Accession For	
NTIS GRA&I	☒
DTIC TAB	☐
Unannounced	☐
Justification	

By_____
Distribution/
Availability Codes

Dist	Avail and/or Special
A-1	

DA FORM 2496
AUG 80

PREVIOUS EDITIONS WILL BE USED

☆ U.S. Government Printing Off.

Immunization Studies With Attenuated Strains of Bacillus anthracis

B. E. Ivins[1]*, J. W. Ezzell, Jr.[1], J. Jemski[2], K. W. Hedlund,[1+]

J. D. Ristroph,[1++] and S. H. Leppla[1]

Divisions of Bacteriology[1] and Airborne Diseases,[2]

U. S. Army Medical Research Institute of Infectious Diseases

Fort Detrick, Frederick, Maryland 21701-5011

*Corresponding author

Telephone: 301/663-7341

+Present address: Department of Rickettsiology,

Walter Reed Army Institute for Research, Washington, D.C. 20307

++Present address: Department of Pathology,

Dwight David Eisenhower Army Medical Center

Fort Gordon, Georgia 30905

Running Title: B. anthracis immunization studies

In conducting the research described in this report, the investigators adhered
to the "Guide for the Care and Use of Laboratory Animals," as promulgated by
the Committee on Care and Use of Laboratory Animals of the Institute of
Laboratory Animal Resources, National Research Council. The facilities are
fully accredited by the American Association for Accreditation of Laboratory
Animal Care.

The views of the authors do not purport to reflect the positions of
the Department of the Army or the Department of the Defense.

ABSTRACT

Live, attenuated strains of Bacillus anthracis lacking either the capsule plasmid pX02, the toxin plasmid pX01, or both plasmids, were tested for their efficacy as vaccines against intravenous anthrax toxin challenge in Fischer 344 rats and against aerosol or intramuscular, virulent anthrax spore challenge in Hartley guinea pigs. Only those animals immunized with toxigenic, non-encapsulated (pX01$^{(+)}$, pX02$^{(-)}$) strains survived toxin or spore challenge and demonstrated post-immunization antibody titers to the three components of anthrax toxin (protective antigen, lethal factor, and edema factor). Immunization with two non-toxigenic, encapsulated (pX01$^{(-)}$, pX02$^{(+)}$), Pasteur vaccine strains neither provided protection nor elicited titers to any of the toxin components. Therefore to successfully immunize against anthrax toxin or spore challenge, attenuated, live strains of B. anthracis must produce toxin components specified by the pX01 plasmid.

INTRODUCTION

Virulent strains of Bacill anthracis possess two plasmid-mediated virulence factors (21): a poly-D-glutamic acid capsule (11), and a tripartite exotoxin (1, 23), consisting of protective antigen (PA), edema factor (EF), and lethal factor (LF). Production of the toxin is controlled by the 110-megadalton (MDa) plasmid pXO1 (formerly pBA1) (16), while synthesis of the capsule is dependent upon the 60-MDa plasmid pXO2 (7, 26). Thus, fully virulent strains ($pXO1^+$, $pXO2^+$) produce both toxin and capsule; $pXO1^+$, $pXO2^-$ strains produce toxin only; $pXO1^-$, $pXO2^+$ strains produce capsule only; $pXO1^-$, $pXO2^-$ strains produce neither toxin nor capsule (7).

In the United States, the currently licensed human vaccine against anthrax consists of an aluminum hydroxide precipitate of supernatant material from a toxigenic non-encapsulated strain of B. anthracis, V770-NP1-R (18). Immunization with this vaccine, which is composed primarily of protective antigen (9), requires a series of six doses over an 18-month period, followed by boosters at yearly intervals. For immunization of livestock against anthrax, a suspension of viable spores of the toxigenic, non-encapsulated Sterne strain is commonly employed (25).

The first anthrax vaccines which were widely used in livestock during the late 1800s and early 1900s were the Pasteur-type vaccines (17, 28, 29), which consisted of cultures of virulent anthrax bacilli attenuated by growth at 42-43°C. Unfortunately, these vaccines varied greatly in their degrees of attenuation (28, 29). Some of the cultures were sufficiently virulent to kill the animals being inoculated (13), while others were so attenuated that they conferred no immunity to infection (27, 28). An explanation for the molecular

mechanism of attenuation of Pasteur-type vaccines was recently proposed by
Mikesell et al., who demonstrated that culturing $\underline{B.}$ $\underline{anthracis}$ at 42.5°C cures
the bacillus of the toxin plasmid pX01 (16), and thus converts fully virulent
pX01$^+$, pX02$^+$ cells to avirulent pX01$^-$, pX02$^+$ cells.

The studies reported here are part of the continuing research toward the
development of a more protective and less reactogenic human anthrax vaccine.
Their purpose was to compare $\underline{B.}$ $\underline{anthracis}$ strains lacking one or both primary
virulence factors (and their respective plasmids) with respect to their
efficacy in immunizing experimental animals against anthrax toxin or spore
challenge, and to compare the effectiveness of various vaccine administration
regimens. Additionally, these studies sought to further elucidate the nature
of Pasteur's early anthrax vaccines and to provide an explanation for their
immunizing efficacy.

MATERIALS AND METHODS

Bacterial strains. The B. anthracis strains used in this study are listed in Table 1.

Experimental animals. Male, 200-300g, Fischer 344 rats were employed in the toxin challenge studies. Female, 275-325g, Hartley guinea pigs were used for the spore challenge studies.

Immunization and challenge studies. Fischer 344 rats (5 per group) and Hartley guinea pigs (7-9 per group) were immunized intramuscularly (i.m.) either with attenuated-strain vegetative cells from late log-phase R medium cultures (19), or with the currently licensed human anthrax vaccine (2, 18) prepared by the Michigan Department of Public Health and designated in this report as MDPH. For anthrax toxin challenge studies, groups of rats were immunized with 2×10^7 CFU of B. anthracis Sterne, Pasteur 4229, ΔVollum 1B-1, ΔVollum 1B-3, ΔSterne-1, or ΔV770-NP1-R-strain cells twice weekly for four weeks, then given a final boost at 5 1/2 weeks. At six weeks, one ml of R medium culture supernatant containing 62 toxic units (TU) (8) of crude Vollum 1B anthrax lethal toxin (approximately 25 μg PA and 3 μg LF) (6) was injected into the dorsal penile veins of the rats, and times to death (TTD) in min were recorded. For i.m. spore challenge studies, several vaccination regimes employing various B. anthracis strains were employed. Each group of guinea pigs was immunized according to one of the following schedules: i) two injections, spaced two weeks apart, of 10^6 CFU B. anthracis Sterne-strain cells; ii) two injections, spaced two weeks apart, of 10^7 CFU B. anthracis ΔVollum 1B-1, Pasteur 4229, or ΔSterne-1-strain cells; iii) four biweekly

injections of 10^8 CFU B. anthracis ΔTexas-1 or ΔTexas-2-strain cells; and iv)
four biweekly injections of B. anthracis Texas-strain cells with the first
injection containing 500 CFU; second, 1500 CFU; third, 5000 CFU; and fourth,
10,000 CFU. Two weeks following the final immunization, all animals received
1500 (approximately 30 i.m. LD_{50}) Vollum 1B spores. Times to death in days
were recorded. and Harmonic mean TTD were calculated in order to provide a
better indication of the overall survival of each group of guinea pigs (3,
4). For aerosol spore challenge studies, groups of guinea pigs were immunized
either with B. anthracis Sterne, ΔVollum 1B-3, ΔTexas-1, ΔSterne-1, Pasteur
4229, or Pasteur 6602-strain cells in four biweekly doses of 10^7 CFU, or with
MDPH in three biweekly doses of 0.5 ml. Two weeks following the final
immunization, the guinea pigs were placed in a modified Henderson aerosol
apparatus (12, 15, 20) for 10 minutes and allowed to inhale either 1.58 x 10^6
(26 aerosol LD_{50}) or 2.09 x 10^6 (35 aerosol LD_{50}) virulent Vollum 1B spores.
Times to death in days were recorded, and the Harmonic mean TTD were
calculated.

   Serological studies. PA, EF, and LF were purified from R medium culture
supernatants of B. anthracis Sterne as previously described (14). Post-
immunization sera from rats and guinea pigs were titered for antibody against
the three toxin components by enzyme-linked immunosorbent assay (ELISA). For
the assays, microtiter plate (Linbro) wells were coated with PA, EF or LF (100
μl of a 1 μg/ml solution in 0.05 M sodium borate, pH 9.5) Following
incubation for 4 h at 37°C or overnight at 4°C, 160 μl of either bovine serum
albumin (BSA) or gelatin (1 mg/ml in 5 mM HEPES, 0.15 M NaCl, pH 7.5) was
added to each well, and the plates were reincubated for 30 minutes at 25°C.
The wells were washed twice with 300 μl phophate buffered saline + Tween 20

(PBST) (0.85% sodium chloride, 10 mM sodium phosphate, 0.05% Tween 20). One hundred and fifty microliters of PBST + 5% fetal calf serum (PBSTF) or 0.1% gelatin (PBSTG) was added to each well. Fifty microliters of each serum sample to be tested was added to the first well in a row, then serially diluted 1:4 down the row. The plates were incubated overnight at $4^{O}C$ and then washed twice with PBST. For guinea pig sera, each well received 100 μl of horseradish-peroxidase-Protein A conjugate in PBST (final conjugate concentration=1 μg/ml). For rat sera, each well received 100 μl of goat, anti-rat horseradish-peroxidase conjugate in PBSTG (final conjugate concentration=1 μg/ml). Plates were incubated at $25^{O}C$ for 60 min then washed 5X with PBST. Substrate (2,2'-azino-bis(3-ethylbenzthiazdinesulfonic acid) (Sigma) was dissolved in 0.1 M sodium citrate, pH 4.0, to a concentration of 1 mg/ml. Hydrogen peroxide (0.003%) was then added, and the substrate + H_2O_2 solution was dispensed into the wells in 100 μl aliquots. After incubating 30 min, reactions were terminated by addition of 10% sodium dodecyl sulfate, 50 μl per well. Absorbances at 414 nm were determined with a Dynatech MR580 ELISA reader. Absorbance values which exceeded negative control values by greater than 2.1-fold were scored as positive [27]. The mean titers of sera from immunized animals compared to those from unimmunized controls were statistically analyzed using one way analysis of variance and Fisher's Least Significant Difference Test [24].

To demonstrate that animals vaccinated with the various attenuated strains had received sufficient antigenic stimulus to engender an immune response, post-vaccination sera from the guinea pigs were examined for activity in a B. anthracis whole-cell ELISA system. Experimental conditions were identical to those described above, with two exceptions: a) 10^7 vegetative Sterne-strain cells in PBS were added to each well of a 96-well tissue culture plate (Costar), which was then dried overnight at 25oC and heated to 60oC for 30 min

to fix the cells to the wells; and b) rather than serial dilutions, a single

1:4 dilution of each serum sample was assayed. ELISA absorbance values for

serum samples from vaccinated animals were qualitatively compared with values

for sera from unvaccinated control animals. Statistical analyses on data were

performed as described above.

RESULTS

Immunization of rats against toxin challenge. As demonstrated by the data in Table 2, rats immunized with the Sterne ($pX01^+$, $pX02^-$) strain cells were completely protected from lethal toxicity, and they exhibited significant titers to PA, LF, and EF ($P<0.05$). Rats immunized with strains containing only pX02 or with strains containing neither plasmid, however, showed no evidence of protection in that they neither survived nor exhibited an extended TTD. Furthermore, no post-vaccination titers to PA, LF, or EF could be demonstrated in these animals.

Immunization of guinea pigs against intramuscular spore challenge. Since the toxigenic, nonencapsulated Sterne strain had been demonstrated to be an effective live vaccine against toxin challenge, it was decided in the i.m. spore challenge studies to also test another $pX01^+$, $pX02^-$ strain, Texas, and two of its plasmid-cured derivatives, ΔTexas-1 and ΔTexas-2. Texas is a clinical isolate of B. anthracis which, like the Sterne strain, produces all three toxin components but does not produce a capsule. Several different immunization regimens were employed to determine whether the size of dose or number of doses affected the guinea pig responses to spore challenge. The data in Table 3 demonstrate that immunization with Sterne-strain cells resulted in complete protection for the animals. Furthermore, immunization with Texas-strain cells was also completely protective. No animals vaccinated with B. anthracis cells lacking pX01 survived challenge or had significant titers ($P<0.05$) to PA, LF, or EF. Texas-strain-immunized animals demonstrated titers to all three toxin components. Sterne-immunized guinea pigs had significant titers to PA and LF, but not EF.

Immunization of guinea pigs against aerosol spore challenge. Although vaccination with B. anthracis strains lacking pX01 did not provide protection against intravenous toxin challenge or i.m. spore challenge, it remained possible that vaccination with such strains might afford protection against an aerosol spore challenge. The data in Table 4 demonstrate that although vaccination with either MDPH vaccine or live Sterne-strain cells afforded substantial protection to aerosol-challenged guinea pigs, immunization with strains lacking pX01 neither afforded survival to the animals nor extended their mean TTD. Significant titers ($P<0.05$) to the three toxin components were evident only in sera from animals vaccinated with Sterne cells or MDPH.

Serological response to immunization. Post-vaccination sera from all groups of guinea pigs immunized with the various B. anthracis strains were compared in the whole-cell ELISA system with sera from an unimmunized control group. Vaccinated animals, regardless of the immunization regimen, demonstrated ELISA absorbance values significantly higher ($P<0.01$) than the absorbance values of the unvaccinated control group (data not shown). Thus, the immunization regimens for the various strains were sufficient in all cases to stimulate an antibody response to cell-surface antigens, albeit the response in animals receiving pX01⁻ strains was not protective.

DISCUSSION

From the data in this study, comparing the relative immunizing efficacies of ten attenuated strains of B. anthracis (see Table 1), it is clear that vaccination with cells lacking the pX01 plasmid confers no protection against either anthrax toxin or spore challenge. This is in contrast to immunization with non-encapsulated, toxin-producing (pX01$^+$, pX02$^-$) strains such as Sterne or Texas, which are fully protective under a variety of immunizing regimens, i.e. several large doses, a few small doses, or a series of graded doses. The finding that ELISA titers were elicited to PA, LF, and EF only in animals vaccinated with strains containing plasmid pX01 provides further evidence that functional toxin component structural genes are not present on the B. anthracis chromosome, but only on pX01. Immunization with the MDPH human vaccine elicited titers to EF and LF as well as PA, indicating that the human "protective antigen" vaccine in fact contains all the toxin components. The protection and serological studies reported here thus indicate that to protect animals against a large anthrax toxin or spore challenge, one or more toxin components must be present in a chemical vaccine or produced by a live vaccine. The finding that vaccination with B. anthracis cells (pX01$^-$, pX02$^+$) producing capsule but not toxin was not protective supports previous reports that the D-glutamyl polypeptide capsule of the organism is not an important immunogen (10, 22). The finding, however, does not explain how Pasteur's heat attenuation regimen, which causes the selective loss of pX01 (7, 16), was able to produce a successful live anthrax vaccine. It does further emphasize the apparent paradox between Pasteur's original vaccine strains and the Pasteur-type strains available from the American Type Culture Collection which are

completely ineffectual as immunogens. The current hypothesis to explain Louis
Pasteur's mechanism of attenuation of $\underline{B}$. $\underline{anthracis}$ is that by growing virulent
cells at elevated temperatures, he induced the loss of the pX01 toxin plasmid
(16), resulting in an increased proportion of pX01⁻, pX02⁺ cells and a
decreased proportion of virulent, pX01⁺, pX02⁺ cells in the cultures. Since
our studies have clearly demonstrated that pure cultures of pX01⁻, pX02⁺ $\underline{B}$.
$\underline{anthracis}$ cells are not effective live vaccines, we believe the efficacy of
Pasteur's vaccines can be attributed to the presence of small numbers of
pX01⁺, pX02⁺ bacteria, and that subclinical infection by these bacteria would
have induced a protective immune response. Evidence that Pasteur's vaccine
did indeed contain virulent cells was provided by Pasteur himself. He
demonstrated that serial passage of the attenuated cultures through day-old
guinea pigs restored virulence (5), apparently by selecting for the virulent
bacilli present. The fact that the Pasteur-type strains from the American
Type Culture Collection contain only the pX02 plasmid (7) while those from the
Japanese collection contain both plasmids (26) must reflect the differing
results obtained when pure culture technique was applied to Pasteur's mixed
cultures without recognition that a mixture was present.

ACKNOWLEDGEMENTS

LITERATURE CITED

1. Beall, F. A., M. J. Taylor, and C. B. Thorne. 1961. Rapid lethal effect
    in rats of a third component found upon fractionating the toxins of
    Bacillus anthracis. J. Bacteriol. 83:1274-1280.

2. Brachman, P. S., H. Gold, S. A. Plotkin, F. R. Fekety, M. Werrin, and N.
    R. Ingraham. 1962. Field evaluation of a human anthrax vaccine. Am. J.
    Pub. Health. 52:632-645.

3. Colton, T. 1974. Statistics in medicine, p. 30-31. Little, Brown, and
    Co., Boston.

4. DeArmon. I. A., Jr., F. Klein, R. E. Lincoln, B. G. Mahlandt, and A. L.
    Fernelius. 1961. Immunological studies of anthrax. I. An index to
    determine quantitative immunization. J. Immunol. 87:233-239.

5. Descour. L. 1923. In A. F. Webb and B. H. Webb (ed.), Pasteur and his
    work, p.88, 2nd ed. T. Fisher Unwin. Ltd., London.

6. Ezzell, J. W., B. E. Ivins, and S. H. Leppla. 1984. Immunoelectro-
    phoretic analysis, toxicity, and kinetics of in vitro production of the
    protective antigen and lethal factor components of Bacillus anthracis
    toxin. Infect. Immun. 45:761-767.

7. Green, B. D., L. Battisti, T. M. Koehler, C. B. Thorne, and B. E. Ivins.
    1985. Demonstration of a capsule plasmid in Bacillus anthracis.
    Infect. Immun. 29:291-297.

8. Haines, B. W., F. Klein, and R. E. Lincoln. 1965. Quantitative assay for
    crude anthrax toxins. J. Bacteriol. 89:74-83.

9. Hambleton, P., J. A. Carman, and J. Melling. 1984. Anthrax: the disease
    in relation to vaccines. Vaccine 2:125-132.

10. Ivanovics, G. 1938. Immunity to anthrax. Trans. of Zeitschrift fuer
    Immunitaetsforschung, Allergie und Klinische Immunologie (Germany) 94:436-
    458.

11. Ivanovics, G., and V. Bruckner. 1937. Chemische und immunologische
    studien uber den mechanismus der milzbrandinfektion und immunitat die
    chemische struktur der kapelsubstanz des milzbrand-bacillus und der
    serolisch identischen spezifichen substanz des Bacillus mesentericus.
    Z. Immunitaetsforsch. Exp. Ther. 90:304-310.

12. Jemski, J. V., and G. B. Phillips. 1965. Aerosol challenge of animals, p.
    274-341. In W. I. Gay (ed.), Methods of animal experimentation, Vol. 1,
    Academic Press, Inc., New York.

13. Lechevalier, H. A., and M. Solotorovsky. 1965. Three centuries of
microbiology, p. 196. McGraw-Hill Book Co., New York.

14. Leppla, S. H. 1984. Bacillus anthracis calmodulin-dependent adenylate
cyclase: chemical and enzymatic properties and interactions with
eucaryotic cells, p. 139-198. In P. Greengard and G. A. Robinson (ed.),
Advances in cyclic nucleotide and protein phosphorylation research, vol.
17. Raven Press, New York.

15. May, K. R. 1983. The collision nebulizer apparatus: description,
performance, and application. Aerosol Sci. 4:235-243.

16. Mikesell, P., B. E. Ivins, J. D. Ristroph, and T. M. Dreier. 1983.
Evidence for plasmid-mediated toxin production in Bacillus anthracis.
Infect. Immun. 39:371-376.

17. Pasteur, L. 1881. De l'attenuation des virus et de leur retour a la
virulence. C. Rend. Acad. Sci. Agric. Bulg. 92:429-435.

18. Puziss, M., L. C. Manning, J. W. Lynch, E. Barclay, I. Abelow, and G.
Wright. 1963. Large-scale production of protective antigen of Bacillus
anthracis in anaerobic cultures. Appl. Microbiol. 11:330-334.

19. Ristroph, J. D., and B. E. Ivins. 1983. Elaboration of Bacillus
anthracis antigens in a new, defined culture medium. Infect. Immun.
39:483-486.

20. Roesseler, W. G., and D. A. Kautter. 1962. Modifications to the
    Henderson apparatus for studying airborne infections. Evaluations using
    aerosols of Listeria monocytogenes. J. Infect. Dis. 100:17-22.

21. Smith, H. 1960. Studies on organisms grown in vivo to reveal the bases
    of microbial pathogenicity. Ann. N.Y. Acad. Sci. 88:1213-1229.

22. Smith, H., and R. C. Gallop. 1956. The chemical basis of the virulence
    of Bacillus anthracis. VI: An extracellular immunising aggressin
    isolated from exudates of infected guinea pigs. Br. J. Exptl. Pathol.
    37:144-155.

23. Stanley, J. L., and H. Smith. 1961. Purification of factor I and
    recognition of a third factor of anthrax toxin. J. Gen. Microbiol.
    26:49-66.

24. Steel, R. G. D., and J. H. Torrie. 1960. Principles and procedures of
    statistics, p. 99-107. McGraw-Hill Book Co., Inc., New York.

25. Sterne, M. 1939. The use of anthrax vaccines prepared from avirulent
    (uncapsulated) variants of Bacillus anthracis. Ondersteport J. Vet. Sci.
    Anim. Indust. 13:307-312.

26. Uchida, I., T. Sekizaki, K. Hashimoto, and N. Terakado. 1985. Association of the encapsulation of _Bacillus anthracis_ with a 60 megadalton plasmid. J. Gen. Microbiol. 131:363-367.

27. Voller, A. 1980. Heterogeneous enzyme-immunoassays and their applications, p. 181-195. _In_ E. T. Maggio (ed.), Enzyme-Immunoassay, CRC Press, Inc., Baca Raton.

28. Wilson, G. S., and A. Miles. 1975. Topley and Wilson's principles of bacteriology, virology and immunity, p. 2220-2221, 6th ed. The Williams & Wilkins Co., Baltimore.

28. Wright, G. G. 1965. The anthrax bacillus, p. 530-544. _In_ R. J. Dubos and J. G. Hirsch (ed.), Bacterial and mycotic infections of man, 4th ed. J. B. Lippincott Co., Philadelphia.

TABLE 1. B. anthracis strains

Strain	Primary Virulence Factors	Plasmids[a]	Source
Vollum 1B	Toxin, Capsule	pX01, pX02	USAMRIID[b]
Sterne	Toxin	pX01	USAMRIID
Texas	Toxin	pX01	R.D. Welsh[c]
ΔVollum 1B-1	Capsule	pX02	Derived from Vollum 1B Strain[d]
ΔVollum 1B-3	Capsule	pX02	Derived from Vollum 1B Strain[d]
Pasteur 4229	Capsule	pX02	ATCC[e]
Pasteur 6602	Capsule	pX02	ATCC
ΔV770-NP1-R-1	None	None	Derived from USAMRIID Strain V770-NP1-R[d]
ΔSterne-1	None	None	Derived from Sterne Strain[d]
ΔTexas-1	None	None	Derived from Texas Strain[d]
ΔTexas-2	None	None	Derived from Texas Strain[d]

[a]Plasmid analysis by Green et al. (7), and B. Ivins (unpublished observations).

[b]United States Army Medical Research Institute of Infectious Diseases.

[c]Bovine isolate, Texas A&M University, College Station, Texas.

[d]Passaged daily for 10 days at 42.5°C, then twice purified from isolated colonies.

[e]American Type Culture Collection, Rockville, Maryland.

20

TABLE 2. Immunization of rats against toxin challenge[a]

Immunization		Serological Response[b]			Response to Toxin Challenge	
Strain	Plasmid Content	Anti-PA	Anti-LF	Anti-EF	Survival (%)	TTD[c]
Sterne	pX01	6,400[d]	2016[d]	635[d]	100	----
Pasteur 4229	pX02	<4	<4	<4	0	71.8 ± 2.2
ΔVollum 1B-1	pX02	<4	<4	<4	0	67.3 ± 2.1
ΔVollum 1B-3	pX02	<4	<4	<4	0	67.4 ± 1.5
ΔSterne-1	None	<4	<4	<4	0	68.8 ± 2.9
ΔV770-NPI-R-1	None	<4	<4	<4	0	67.2 ± 1.1
None	---	<4	<4	<4	0	76.0 ± 2.1

[a] Groups of male Fischer 344 rats, 200-300g, were immunized with 2×10^7 CFU of the indicated B. anthracis strain twice weekly for 4 weeks, given a final boost at $5\frac{1}{2}$ weeks, and challenged intravenously with 62 TU of anthrax toxin at 6 weeks.

[b] Reciprocal geometric mean ELISA titers of pre-challenge sera.

[c] Time to death (arithmetic mean minutes ± standard deviation).

[d] Statistically significant compared to unvaccinated controls: $P < 0.05$.

TABLE 3. Immunization of guinea pigs against intramuscular spore challenge

Immunization		Serological Response[a]			Response to spore challenge[b]	
Strain	Plasmid Content	Anti-PA	Anti-LF	Anti-EF	Survival (%)	TTD[c]
Sterne[d]	pX01	25,600[h]	4,526[h]	23	100	---
ΔVollum 1B-1[e]	pX02	8	<4	5	0	2.55
Pasteur 4229[e]	pX02	<4	<4	4	0	2.34
ΔSterne-1[e]	None	<4	<4	4	0	2.22
Texas[f]	pX01	33,779[h]	6,400[h]	8,444[h]	100	---
ΔTexas-1[g]	None	<4	<4	<4	0	2.94
ΔTexas-2[g]	None	<4	<4	5	0	2.42
None	---	<4	<4	4	0	2.24

[a] Reciprocal geometric mean ELISA titers of pre-challenge sera.

[b] Two weeks following the final immunization, the guinea pigs received an i.m. challenge of approximately 30 LD_{50} of Vollum 1B spores.

[c] Harmonic mean time to death (days).

[d] Female Hartley guinea pigs, 275-325g, were given two injections, spaced two weeks apart, of 10^6 CFU Sterne-strain cells.

[e] Guinea pigs were given two injections, spaced two weeks apart, of 10^7 CFU of the indicated strain.

[f] Guinea pigs were given four biweekly injections of Texas-strain cells (first injection, 500 CFU, second, 1,500 CFU; third, 5,000 CFU; fourth, 10,000 CFU).

[g] Guinea pigs were given four biweekly injections of 10^8 CFU of the indicated strain.

[h] Statistically significant compared to unvaccinated controls: $P < 0.05$.

TABLE 4. Immunization of guinea pigs against aerosol spore challenge[a]

Immunization		Serological Response[b]			Challenge	Response to Spore Challenge	
Immunogen	Plasmid Content	Anti-PA	Anti-LF	Anti-EF	Dose (LD_{50})	Survival (%)	TTD[c]
Sterne	pXO1	$16,127^d$	$8,064^d$	504^d	26	100	--
MDPH vaccine	---	$64,508^d$	$3,311^d$	49^d	26	71	20.47
ΔVollum 1B-3	pXO2	4	<4	<4	26	0	3.00
ΔTexas-1	None	4	6	4	26	0	3.53
ΔSterne-1	None	<4	4	<4	26	0	3.86
None	--	<4	<4	<4	26	0	3.11
Pasteur 4229	pXO2	<4	<4	<4	35	0	2.33
Pasteur 6602	pXO2	<4	<4	<4	35	0	2.80
None	---	<4	<4	<4	35	0	2.80

[a] Groups of female Hartley guinea pigs, 275-325g, were immunized either with MDPH (3 biweekly doses of 0.5 ml) or with the indicated B. anthracis strain (10^7 CFU in 4 biweekly doses). Two weeks after the final immunization the animals were given an aerosol challenge of either 26 or 35 LD_{50} of Vollum 1B spores.

[b] Geometric mean ELISA titers of pre-challenge sera.

[c] Harmonic mean time to death (days).

[d] Statistically significant compared to unvaccinated controls: $P<0.05$.